Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Transcriptional profiles of Campylobacter jejuni NCTC 11168 to 0.125mg/L erythromycin treatment

ABSTRACT: Erythromycin is the drug of choice to treat campylobacteriosis, but resistance to this antibiotic is rising. The adaptive mechanisms employed by Campylobacter jejuni to erythromycin treatment remain unknown. The aim of this study is to determine the molecular basis underlying Campylobacter’s immediate response to Ery treatment.

ORGANISM(S): Campylobacter jejuni subsp. jejuni NCTC 11168 = ATCC 700819 Campylobacter jejuni

PROVIDER: GSE43024 | GEO | 2013/10/10

SECONDARY ACCESSION(S): PRJNA184070

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Transcriptional profiles of Campylobacter jejuni NCTC 11168 to 4mg/L erythromycin treatment

2013-10-10 | GSE43023 | GEO

Transcriptional profiles of Campylobacter jejuni NCTC 11168 to 4mg/L erythromycin treatment

Project description:Erythromycin is the drug of choice to treat campylobacteriosis, but resistance to this antibiotic is rising. The adaptive mechanisms employed by Campylobacter jejuni to erythromycin treatment remain unknown. The aim of this study is to determine the molecular basis underlying CampylobacterM-bM-^@M-^Ys immediate response to Ery treatment. The design utilized an available two color microarray slide for the entire transcriptome of Campylobacter jejuni wild type strain NCTC 11168. One hybridizations were performed: sham-treated NCTC 11168 v.s. lethal dose erythromycin treated NCTC 11168. Samples were independently grown and harvested. There were three biological replicates of each sample.

2013-10-10 | E-GEOD-43023 | biostudies-arrayexpress

Transcriptional profiles of Campylobacter jejuni NCTC 11168 to 0.125mg/L erythromycin treatment

Project description:Erythromycin is the drug of choice to treat campylobacteriosis, but resistance to this antibiotic is rising. The adaptive mechanisms employed by Campylobacter jejuni to erythromycin treatment remain unknown. The aim of this study is to determine the molecular basis underlying CampylobacterM-bM-^@M-^Ys immediate response to Ery treatment. The design utilized an available two color microarray slide for the entire transcriptome of Campylobacter jejuni wild type strain NCTC 11168. One hybridizations were performed: sham-treated NCTC 11168 v.s. sub-lethal dose erythromycin treated NCTC 11168. Samples were independently grown and harvested. There were three biological replicates of each sample.

2013-10-10 | E-GEOD-43024 | biostudies-arrayexpress

Transcriptional profiles of Campylobacter jejuni macrolide resistant strain JL272 to 4mg/L erythromycin treatment

2013-10-10 | GSE43025 | GEO

Transcriptional profiles of Campylobacter jejuni macrolide resistant strain JL272 to 4mg/L erythromycin treatment

Project description:Erythromycin is the drug of choice to treat campylobacteriosis, but resistance to this antibiotic is rising. The adaptive mechanisms employed by Campylobacter jejuni to erythromycin treatment remain unknown. The aim of this study is to determine the molecular basis underlying CampylobacterM-bM-^@M-^Ys immediate response to Ery treatment. The design utilized an available two color microarray slide for the entire transcriptome of Campylobacter jejuni macrolide resistant strain JL272. One hybridizations were performed: sham-treated JL272 v.s. lethal dose erythromycin treated JL272. Samples were independently grown and harvested. There were three biological replicates of each sample.

2013-10-10 | E-GEOD-43025 | biostudies-arrayexpress

The transcriptome of erythromycin-resistant Campylobacter jejuni strain selected from NCTC 11168

Project description:Campylobacter, a major foodborne pathogen, is increasingly resistant to macrolide antibibotics. Previous findings suggested that development of macrolide resistance in Campylobacter requires a multi-step process, but the molecular mechanisms involved in the process are not known. In our study, erythromycin-resistant C. jejuni mutant (R) was selected in vitro by stepwise exposure of C. jejuni NCTC11168(S) to increasing concentrations of erythromycin.The resistant were subjected to microarray and the the global transcriptional profile was analyzed. In this series, DNA microarray was used to compare the gene expression profiles of the macrolide-resistant strain with its parent wild-type strain NCTC11168. A large number of gene showed significant changes in R. The up-regulated genes in the resistant strains are involved in miscellaneous periplasmic proteins, efflux protein and putative aminotransferase, while the majority of the down-regulated genes are involved in electron transport, lipoprotein, heat shock protein and unknown function proteins. The over-expression of efflux pump and periplasmic protein was involved in the development of resistance to macrolide in C. jejuni.

2013-08-13 | GSE49257 | GEO

The transcriptome of erythromycin-resistant Campylobacter jejuni strain selected from NCTC 11168

2013-08-13 | E-GEOD-49257 | biostudies-arrayexpress

Differential RNA-sequencing of Campylobacter jejuni NCTC 11168

Project description:We report the use of differential RNA-sequencing for the determination of the primary transcriptome of wildtype Campylobacter jejuni NCTC 11168. This allows for the genome-wide determination of transcription start sites.

2013-09-13 | GSE49312 | GEO

RNA-sequencing of Campylobacter jejuni NCTC 11168 wildtype and fur perR mutant

Project description:We report the use of RNA-seq analysis for the determination of RPKM transcript levels in wildtype and fur perR mutant of Campylobacter jejuni NCTC 11168. This allows for comparison of gene expression levels.

2014-07-01 | GSE49687 | GEO

Screening for novel immunogenic proteins of Campylobacter jejuni NCTC 11168

Project description:The screening of a cDNA derived expression library of Campylobacter jejuni NCTC 11168 expressed in E. coli using a fusion construct and specific HaloTag interaction to a modified surface is shown. 1536 different clones were screened including positive (hisJ, cjaA, peb1a) and negative (argC, pyrC, gapA) reference proteins. The goal of the screening was to identify potential novel immunogenic proteins from C. jejuni by selecting clones showing a high signal intensity in comparison to the known antigens used as positive markers. Afterwards, the most promising clones were sequenced to identify the gene and corresponding protein, and these proteins were then investigated further. Consequently, 22 novel immunogenic proteins could be identified.

2013-04-06 | GSE45268 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data